概要基本信息药物类型小分子化药别名靶点-作用方式调节剂作用机制铁调节治疗领域肿瘤在研适应症肿瘤非在研适应症晚期恶性实体瘤原研机构University of Sydney Union在研机构University of Sydney Union非在研机构Collaborative Medicinal Development LLC权益机构-最高研发阶段临床1期首次获批日期-最高研发阶段(中国)-特殊审评-登录后查看时间轴结构/序列分子式C19H23N5SInChIKeyGNLZNQJBZNOUBM-UHFFFAOYSA-NCAS号1382469-39-7关联1 项与 DpC 相关的临床试验NCT02688101 / Completed临床1期A Phase 1 Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid TumorsMulticenter, open-label, dose-escalation and pharmacokinetic study.开始日期2016-04-11申办/合作机构Collaborative Medicinal Development LLC100 项与 DpC 相关的临床结果登录后查看更多信息100 项与 DpC 相关的转化医学登录后查看更多信息100 项与 DpC 相关的专利（医药）登录后查看更多信息545 项与 DpC 相关的文献（医药）2025-04-15·LangmuirMicellization of Zwitterionic Surfactant with Opposite Dipoles is Differently Affected by AnionsArticle作者: Cortez, Matheus P. ; Lacerda, Caroline D. ; Carretero, Gustavo P. B. ; Chaimovich, Hernan ; Mortara, Laura ; Cuccovia, Iolanda M. ; Schreier, Shirley ; Lima, Filipe S. We used isothermal titration calorimetry to investigate the influence of hydrotropic anions on the micellization of the zwitterionic surfactants N-dodecylphosphocholine (DPC) and N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate (DPS), as well as the effect of these anions on the micellar interface. Our results showed an increased enthalpic contribution to the Gibbs energy for micellization when the hydrotropic anions contained CF3 or C6H5 hydrophobic groups. We found that the critical micelle concentration of DPS was more sensitive to the effects of the anions than that of DPC, likely because the positive charge of DPS is located closer to the micellar core. Overall, the magnitudes of the anion effects on the micellar properties of DPC and DPS were relatively minor compared with those observed in cationic micelles. These findings offer valuable insights into the role of dipole orientation and charge distribution in the interactions between zwitterionic surfactants and anions as well as the effects of hydrotropic anions on these systems.2025-02-01·Annals of Vascular SurgeryAcute Limb Ischemia in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) Support: A Ten-Year Single-Center ExperienceArticle作者: Nejim, Besma ; Flohr, Tanya R ; Sakya, Surav ; Snow, Rachael ; Castello-Ramirez, Maria ; Aziz, Faisal ; Chau, Marvin ; Brehm, Christoph ; Flohr, Tanya R. BACKGROUNDVeno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly utilized as a life-saving modality in patients with cardiopulmonary compromise. Acute limb ischemia (ALI) has been reported when the femoral artery was accessed, and it was associated with higher mortality in patients on extracorporeal membrane oxygenation (ECMO). However, prior studies were limited by small sample size and the lack of long-term follow-up. We aimed to investigate the predictors of ALI in ECMO and the effect of ALI on long-term mortality.METHODSRetrospective institutional chart review was performed. Patients who underwent VA-ECMO (Jan/2008-Jan/2018) were identified. Primary outcomes were ALI and 4-year mortality. Logistic regression analysis was used to investigate the predictors of ALI. Survival analysis methods were used to examine 4-year mortality.RESULTSA total of 377 patients were included. Vascular complications took place in 149 (39.5%) patients. The majority was ALI (107, 75.4%). Eleven patients had limb loss. ALI patients were younger (mean age: 50.2 ± 15.9 vs. 54.1 ± 15.5; P = 0.03), were more likely to have history of peripheral arterial disease (PAD) (7.6% vs. 3.0%; P = 0.047), were less likely to be on aspirin (40.2% vs. 54.4%; P = 0.013), and were more likely to be on vasopressors (97.1% vs. 88.0%; P = 0.007). Arterial cannula size was not associated with ALI so as the concurrent use of ventricular offloading devices (intra-aortic balloon pump or Impella (Abiomed Inc, Dancers, MA)). The use of distal perfusion catheter (DPC) was not protective against ALI in this cohort. However, DPC was associated with less likelihood to require vascular intervention (20.1% vs. 32.0%; P = 0.009). In adjusted analysis, aspirin use was protective against ALI [adjusted odds ratios (aOR) 95% CI: 0.52(0.30 - 0.90); P = 0.018]. The only predictor of ALI was the use of vasopressors [aOR (95% CI): 6.8 (1.5 - 30.4); P = 0.012]. For those who were successfully decannulated, 4-year survival was 65.1% in patients without ALI versus 46.8% in ALI (P = 0.044). After adjusting for potential risk factors, 4-year mortality hazard was significantly higher in patients with ALI [HR: 1.80(1.04 - 3.12); P = 0.035].CONCLUSIONSPatients requiring ECMO are critically ill. The development of ALI is detrimental to this population. This effect extends beyond the acute period. ALI increased 4-year mortality risk by 80%. The use of DPC did not protect against ALI, but it was associated with less vascular interventions.2024-12-01·Food Chemistry: XUpcycling date juice waste: Impact of date press cake on sponge cake qualityArticle作者: Farahnaky, Asgar ; Karambakhsh, Golsa ; Golmakani, Mohammad Taghi ; Houshmandi, Parisa ; Majzoobi, Mahsa Date press cake (DPC) is the main waste stream of date fruit juice extraction. The primary aim of this research was to explore the potential of DPC as a novel food component, using sponge cake as a case study, to upcycle waste from date fruit processing. Thus, different concentrations (0 %, 10 %, 20 %, 30 %, and 40 %) and particle sizes (210 and 500 μm) of DPC were tested on the quality characteristics during storage for 1, 7, and 14 days. While the protein content remained constant, a decrease in particle size was found to increase the fat content from 4.48 % to 5.37 % and decrease the fiber content from 14.35 % to 9.13 %. In addition, the consistency and density of the cake batter increased while increasing the concentrations and decreasing the DPC particle sizes. The height, volume, cohesiveness, and springiness of the cake decreased, and its density, hardness, gumminess, and chewiness increased, by decreasing the DPC particle sizes, the increase in its levels and the storage days.100 项与 DpC 相关的药物交易登录后查看更多信息外链KEGGWikiATCDrug Bank---DB15235研发状态10 条进展最快的记录, 登录 后查看更多信息适应症最高研发状态国家/地区公司日期晚期恶性实体瘤临床2期澳大利亚 Collaborative Medicinal Development LLC2016-04-11肿瘤临床1期-University of Sydney Union-登录后查看更多信息临床结果适应症分期评价查看全部结果研究分期人群特征评价人数分组结果评价发布日期 No Data
登录后查看更多信息转化医学使用我们的转化医学数据加速您的研究。登录或查看完整样例数据药物交易使用我们的药物交易数据加速您的研究。登录或查看完整样例数据核心专利使用我们的核心专利数据促进您的研究。登录或查看完整样例数据临床分析紧跟全球注册中心的最新临床试验。登录或查看完整样例数据批准利用最新的监管批准信息加速您的研究。登录或查看完整样例数据特殊审评只需点击几下即可了解关键药物信息。登录或查看完整样例数据